HD-OPM Archive
Hashtags

#ncpv

18 posts

About 95% of acute-thrombosis heart attacks involve soft plaque, not calcified plaque

Oct 03, 2026 · Louis Nervegna ♥ 9 · 💬 9 Plaque, CAC & CT angiography

The post says about 64% of heart attacks from acute thrombosis come from rupture of soft lipid-rich plaque and about 25% from erosion of soft plaque, while only about 5% involve calcified nodules. Because statins and other lipid-lowering drugs stabilize and reverse soft plaque, the poster argues they address the plaque type most responsible for heart attacks.

Nicola Guess: Keto-CTA plaque rose ~20 mm3 in 1 year vs ~13 mm3 over 3 years in PARADIGM

Apr 12, 2025 · Louis Nervegna ♥ 7 · 💬 8 Plaque, CAC & CT angiography

Louis shares Dr. Nicola Guess's critique of the Keto-CTA study: the abstract omitted the registered primary outcome (non-calcified plaque volume), but the figure suggests a rise of ~20 mm3 in one year in lean keto dieters. In PARADIGM, high-risk people on Western diets rose ~13 mm3 over three years (about 17 mm3 with metabolic syndrome). With no control group, the comparison suggests accelerated soft plaque growth.

DISCO-CT diet-plus-medication group showed plaque reversal, unlike progression in Keto-CTA

Jul 17, 2025 · Louis Nervegna ♥ 6 · 💬 6 Plaque, CAC & CT angiography

Louis shares a comparison of non-calcified plaque volume changes across several CT angiography studies. The DISCO-CT intervention group (statins, other medications and a DASH diet) showed significant plaque reversal at one year, while the Keto-CTA group of lean mass hyper-responders with LDL-C around 237 mg/dL showed progression. The linked Keto-CTA longitudinal paper is retracted per link metadata.

Keto-CTA plaque progression vs plaque regression on Repatha in Budoff's other study

Apr 09, 2025 · Louis Nervegna ♥ 8 · 💬 2 Plaque, CAC & CT angiography

Louis compares non-calcified plaque volume (NCPV) changes in the Keto-CTA (LMHR) study with a second Matthew Budoff study in higher-risk people whose LDL was lowered to about 30 mg/dL with the PCSK9 inhibitor Repatha. The lean, healthy keto group with LDL 254 mg/dL progressed, while the hypertensive, higher-risk Repatha group mostly showed major regression. He also notes that uL and mm^3 are the same unit when comparing NCPV across studies.

Repatha alone reversed soft plaque in 37 of 47 patients over 18 months at LDL near 30

Nov 13, 2026 · Louis Nervegna ♥ 9 · 💬 1 PCSK9, ezetimibe & newer drugs

Louis explains a small uncontrolled study of the PCSK9 inhibitor evolocumab with CT angiography. Average LDL was about 30 mg/dL, 37 of 47 patients had some non-calcified plaque regression, and many had large reversals worth years of typical growth (about 5 mm3 per year). He cautions it was small with no randomization or control group, and that PCSK9 monotherapy is not yet proven to reduce heart attacks.

Keto-CTA hyper-responders progressed soft plaque 3.8x faster than Nature-CT controls

Apr 18, 2025 · Louis Nervegna ♥ 5 · 💬 1 Plaque, CAC & CT angiography

Louis compares Keto-CTA (keto diet, LMHR) with the Nature-CT study, both from Budoff's UCLA group using CCTA and Cleerly software, with similar age (~55), no diabetes and no statins. After one year non-calcified plaque volume rose 18.8 mm3 in LMHR versus 4.9 mm3 in the Nature-CT standard-diet group. Budoff reportedly agrees it is a good comparison and plans a paper comparing them.

Letter to JACC: Keto-CTA omitted pre-specified outcome, a 43% rise in non-calcified plaque

Apr 21, 2025 · Louis Nervegna ♥ 4 · 💬 1 Plaque, CAC & CT angiography

Louis shares a letter to the editor critiquing the Keto-CTA study of lean mass hyper-responders. It argues the primary outcome (non-calcified plaque volume) was not reported in the paper, but the lead author later shared a median increase of 18.8 mm3 (~43%), several-fold above normal annual progression and in contrast to regression seen in DISCO-CT. The 0.8% rise in percent atheroma volume also exceeds typical annual change in PARADIGM.

Keto-CTA plaque growth matched diabetics' and far exceeded high-risk statin-treated groups

Apr 16, 2025 · Louis Nervegna ♥ 4 · 💬 1 Plaque, CAC & CT angiography

Louis quotes an analysis of the Keto-CTA trial putting its plaque progression in context: median non-calcified plaque rose 18.8 mm3 in one year, comparable to type 2 diabetics (~17.4 mm3/yr), about triple PARADIGM metabolically normal people, and nearly 3x SMARTool high-risk non-statin users (6.4 mm3/yr). PAV rose 0.8% overall and 2.4% in those with CAC over 100.

Keto-CTA omitted its primary plaque outcome: median NCPV rose 18.8 mm3, 2.5x forecast

Apr 13, 2025 · Louis Nervegna ♥ 6 Plaque, CAC & CT angiography

Louis quotes Alex Leaf's critique: the Keto-CTA paper barely mentioned non-calcified plaque volume (NCPV), the primary outcome, saying only 'most participants presented with stable NCPV'. The lead author later gave a median increase of 18.8 mm3, over 2.5x the 7 mm3 predicted, comparable to metabolic syndrome over 3 years or type 2 diabetes per year, and nearly 3x SMARTool high-risk non-statin users.